$11 billion

Likely valuation for Acceleron Pharma as it seeks a buyer at $180 a share

The identity of the potential buyer couldn’t be immediately learnt. Several global drugmakers, including BristolMyers Squibb Co., which owns 11.5 per cent of Acceleron’s stock, are seen as obvious potential suitors, said the people, who asked not to be identified because the information was private.

Acceleron’s stock has risen sharply over the past 10 days, surging from $130-a-share in mid-September to close at $167.65 on Friday in New York, meaning a deal at $180 would be a 40 per cent premium to when discussions likely began, for a total value of more than $11 billion.